Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the digestive tract, and most GISTs have oncogenic KIT gene mutations, which encode constitutively activated forms of the KIT receptor tyrosine kinase protein. KIT activation is an early and essential event in the development of most GISTs, and KIT inhibition by imatinib mesylate (STI571, Gleevec s ) has been effective therapeutically in patients with GIST (Joensuu et al., 2001; van Oosterom et al., 2001; Demetri et al., 2002) . Despite the excellent overall success of imatinib in GISTs, some patients do not benefit from the drug, and responding patients can eventually develop resistance. It is therefore important to determine the key pathways that convey the oncogenic KIT signal, as these pathways might be targeted to provide synergies with KIT inhibition.
GISTs share ultrastructural and immunohistochemical features with the interstitial cells of Cajal (ICC), and it is likely that GISTs arise from an ICC progenitor cell (Kindblom et al., 1998; Sircar et al., 1999) . ICCs are mesenchymal pacemaker cells that coordinate peristaltic activity throughout the gastrointestinal tract. Differentiation and proliferation of ICCs are dependent on KIT expression, and KIT knockout mice show ICC hypoplasia and aperistalsis (Huizinga et al., 1995) . KIT mutation is an early and potentially initiating event in GISTs, as evidenced by germline KIT mutations in familial GIST syndromes, and by the occurrence of GISTs in a transgenic KIT gain-of-function mouse model Hirota et al., 2000; Isozaki et al., 2000; Beghini et al., 2001; Maeyama et al., 2001; Sommer et al., 2003) . In addition, KIT mutations are found in asymptomatic small GISTs . These observations suggest that most GISTs depend on KIT activation.
KIT belongs to the type III receptor tyrosine kinase (RTK) family, which also includes platelet-derived growth factor receptor alpha (PDGFRA), plateletderived growth factor receptor beta (PDGFRB), colony stimulating factor-1 receptor (CSF1R) and FMS-related tyrosine kinase 3 (FLT3) (Yarden et al., 1987) . The type III RTKs are characterized by five extracellular immunoglobulin-like repeats and a kinase insert separating the ATP-binding and phosphotransferase regions of the kinase domain. The physiologic activation of wildtype KIT is accomplished by binding to its ligand, stem cell factor (SCF), which promotes KIT dimerization, kinase activation, and tyrosine crossphosphorylation. However, these normal mechanisms of KIT activation can be subverted by oncogenic mutations, which contribute to constitutive activation of the receptor Rubin et al., 2001; Heinrich et al., 2003a, b; Sommer et al., 2003) . Most GISTs have oncogenic KIT mutations within exons 9 or 11, which encode parts of the extracellular and intracellular juxtamembrane regions, respectively. Much smaller numbers of GISTs have oncogenic KIT mutations within exons 13 or 17, which encode parts of the kinase domain. All KIT mutations in GISTs, irrespective of the affected domain, appear to be associated with gain of function, as manifested by constitutive KIT tyrosine phosphorylation (Ernst et al., 1998; Hirota et al., 1998; Lasota et al., 1999; Taniguchi et al., 1999; Lux et al., 2000; Rubin et al., 2001) .
The phosphorylated KIT receptor stimulates intracellular signaling pathways controlling cell proliferation, adhesion, apoptosis, survival, and differentiation. These pathways include the RAS/RAF/MAPK and PI3-K/ AKT cascades, which might be regulated by the known binding of GRB2 and PI3-K to the phosphorylated forms of KIT tyrosine residues 703 and 721, respectively (Lev et al., 1992; Thommes et al., 1999) . Furthermore, the signal transducer and activator of transcription (STAT) family of proteins, namely STAT1, STAT3, and STAT5, has been implicated in KIT signaling (Deberry et al., 1997; Brizzi et al., 1999; Linnekin, 1999; Taylor and Metcalfe, 2000) . However, there is evidence that oncogenic KIT proteins can signal differently from wildtype KIT. Immortalized hematopoietic progenitor cells expressing D816V gain-of-function KIT oncoproteins -as found commonly in mast cell disease -have little or no MAPK p42/44 activation, whereas SCFmediated activation of wildtype KIT in these cells results in substantial MAPK p42/44 activation (Chian et al., 2001) . Differences in the biology of wildtype versus mutant KIT were also seen after expression of juxtamembrane KIT mutants in Ba/F3 and bone marrow mast cells (Casteran et al., 2003) . Namely, the KIT juxtamembrane mutants were more effective in activating STAT proteins, and more sensitive to therapeutic inhibition, compared to cells expressing wildtype KIT. It is therefore conceivable that oncogenic KIT signaling in GISTs differs qualitatively from physiologic KIT signal transduction in the ICC lineage.
The aims of our study were to characterize oncogenic KIT signaling mechanisms in GISTs, and to determine which signaling pathways might be of potential relevance to therapeutic interventions. Activation of signaling intermediates was evaluated in GISTs with different KIT mutational mechanisms to evaluate the relevance of the type of KIT mutation for differential activation of signaling pathways. Furthermore, the effects of SCFmediated KIT activation and imatinib-mediated KIT inhibition on signal activation were studied in GIST cell cultures to investigate their dependency on the oncogenic KIT signal.
Results

KIT activation in primary GISTs
KIT activation in primary GISTs was evaluated by Western blotting with antibodies to KIT phosphotyrosines Y703 and Y721 (Figure 1 , and data not shown), which are association sites for the GRB2 and PI3-K proteins, respectively (Yarden et al., 1987; Thommes et al., 1999) . All GISTs had demonstrable KIT expression and most GISTs had constitutive KIT Figure 1 Expression of tyrosine phosphorylated (Y703) and total KIT in immunoblots of total cell lysates from primary GISTs with KIT mutations in exons 9, 11, 13, and 17, and in cell cultures of GIST544 (heterozygous KIT exon 9 mutant) þ /À SCF, and GIST882 (homozygous KIT exon 13 mutant) þ /À imatinib. KIT exon 11 mutations included in-frame deletions (four cases), missense mutations (four cases) and an in-frame insertion (one case). The upper band in the phospho-KIT stain is the 145 kDa mature form of KIT, whereas the upper and lower bands in the total KIT stain are mature and immature 145/125 kDa KIT forms, respectively. Lower bands in the phospho-KIT stain are phosphorylated immature KIT in some samples (e.g. GIST882) but are crossreacting proteins in others (e.g. GIST544). Abbreviations: Ex, exon; Ins, insertion; SCF, stem cell factor; Imat, imatinib phosphorylation, but levels of total and phosphorylated KIT varied substantially from tumor to tumor, even between those having identical KIT mutations. KIT phosphorylation at Y703 and Y721 was particularly low in three GISTs with KIT exon 11 deletions (Figure 1 ). Total KIT protein expression correlated poorly with the level of KIT phosphorylation at Y703 and Y721 suggesting that KIT expression itself is not the key determinant of the variations in KIT phosphorylation at these residues in different primary GISTs (Figure 1 ). KIT tyrosine phosphorylation was further induced by SCF treatment of GIST544 cells, which express a heterozygous KIT exon 9 mutation. By contrast, we have shown previously that KIT phosphorylation was not induced by SCF treatment of GIST882 cells, which carry a homozygous KIT exon 13 mutation (Lux et al., 2000) . These findings suggest that SCF-induced KIT hyperphosphorylation, and associated hyperactivation of downstream signaling pathways (see below), are mediated by activation of the wildtype KIT receptor in GIST544 cells. KIT phosphorylation was inhibited by imatinib treatment in GIST882 cells (Figure 1 ), as reported previously .
KIT oncogenic signaling in primary GISTs
Given that KIT Y703 and Y721 were phosphorylated in most primary GISTs (Figure 1 ), we next evaluated expression and phosphorylation of MAPK, AKT, and S6K. These studies show that the expected downstream signaling intermediates are activated in many, but not all, GISTs. For example, MAPK p42/44 phosphorylation was not demonstrable in four GISTs (Figure 2a ), despite expression of phospho-KIT and total MAPK p42/44 in these tumors. Notably, presence or absence of MAPK p42/44 phosphorylation was not dictated entirely by the KIT mutational mechanism. Three GISTs with identical exon 9 KIT mutations had substantial MAPK p42/44 phosphorylation, whereas a fourth GIST with the same exon 9 KIT mutation did not.
AKT phosphorylation was also variable (Figure 2a ), being relatively low in four KIT exon 9 mutant GISTs, and relatively high in four of nine GISTs with KIT exon 11 mutations. Phosphorylation of the AKT effectors p70S6K/p85S6K did not correlate closely with AKT phosphorylation levels, in that two GISTs expressed phospho-S6K without apparent phosphorylation of AKT, and three GISTs expressed phospho-AKT without apparent expression of phospho-S6K (Figure 2a ). S6K T389 phosphorylation in primary GISTs was generally more prominent in the p85 than in the p70 isoform, whereas S6K T421/S424 phosphorylation was relatively more pronounced for the p70 isoform. However, total p70S6K was expressed at substantially higher levels compared to p85S6K, and therefore the per molecule S6K phosphorylation was highest for the p85 isoform, irrespective of the phosphorylation site examined ( Figure 2a ).
SCF-mediated KIT activation in GIST544 and imatinib-mediated KIT inhibition in GIST882, were accompanied by activation and inhibition, respectively, of MAPK p42/44, AKT, and p70/p85S6K (Figure 2a ). These findings suggest that activation of MAPK p42/44 and PI3-K/AKT pathway proteins is dependent on KIT signaling in GISTs (Figure 2 ). By contrast, JNK was expressed but not phosphorylated in all primary GISTs, and was not activated following SCF treatment of GIST544 cells (data not shown).
Signal transducer and activator of transcription (STAT) proteins have been implicated in oncogenic signaling by KIT and other receptor tyrosine kinase proteins. Phospho-STAT1 expression varied considerably in the primary GISTs (Figure 2b ), but generally paralleled total STAT1 expression in each tumor. Therefore, expression of total STAT1 might be the primary mechanism for regulating STAT1 activation in GISTs. The levels of STAT1 and phospho-STAT1 expression were higher in GISTs with KIT exon 11 missense mutations compared to those with exon 11 deletion or insertion mutations, and expression was also high in three of four GISTs with KIT exon 9 mutations (Figure 2b ). STAT3 phosphorylation at Y705 was found in most of the primary GISTs with exon 11, 13, and 17 mutations, but was weak in the four GISTs with exon 9 mutations (Figure 2b ). By contrast, STAT5 activation was not detected in any GIST, although all GISTs expressed STAT5 at comparable or higher levels compared to the K562 cell line that served as a positive control for STAT5 phosphorylation. Notably, SCF treatment of GIST544 did not increase the constitutive levels of STAT1 and STAT3 activation, and did not result in STAT5 activation. Similarly, imatinib treatment of GIST882 did not bring about apparent inhibition of the constitutive STAT1 and STAT3 activation, although this finding must be qualified by the fact that STAT3 activation was relatively low in the untreated GIST882 cells, and that subtle alterations in STAT3 phosphorylation might therefore have gone undetected. Overall, these observations suggest that STAT1 and STAT3 activation can be KIT-independent in the GIST cell context.
Proliferation and apoptosis in untreated primary GISTs
Expression of the PCNA and cyclin A proliferation markers was variable in the primary GISTs (Figure 3) . Overall, GISTs with KIT exon 9 mutations expressed PCNA and cyclin A weakly. PCNA and cyclin A expression, in general, paralleled phospho-AKT, but did not correlate with phospho-KIT (Figures 1, 2a, and 3) . Expression of the p27 antiproliferative check-point protein was quite uniform in the primary GISTs, particularly amongst those with KIT exon 11 mutations (Figure 3) . PARP cleavage was seen in one primary GIST with a KIT exon 9 mutation suggesting the occurrence of intratumoral apoptosis.
Effects of KIT inhibition on GIST cell proliferation and apoptosis
Imatinib-mediated KIT inhibition in GIST882 cells was accompanied by decreased PCNA and cyclin A expression, and by increased p27 expression (Figure 3) . Apoptotic response, manifested by PARP cleavage, was detectable at 36 h and prominent at 72 h after imatinib treatment (Figure 3 ).
Discussion
Most GISTs have activating mutations of the KIT receptor tyrosine kinase leading to its constitutive activation. KIT oncoproteins are detected early during GIST tumorigenesis, and their therapeutic inhibition by imatinib has dramatic clinical benefits in these otherwise chemo-and radiotherapy resistant tumors (van Oosterom et al., 2001; Demetri et al., 2002) . Despite the central role of oncogenic KIT activation in GIST pathogenesis, little is known about the intracellular signaling events triggered by oncogenic KIT in these tumors. Moreover, it is unclear whether oncogenic mutations in different regions of KIT activate distinct downstream signaling pathways in GISTs. This is not only of biological but also potential clinical relevance, Figure 2 Expression of phosphorylated and total MAPK (p42/44), AKT, and S6K (a) and STAT1, STAT3, and STAT5 (b) in immunoblots of total cell lysates from primary GISTs with KIT mutations in exons 9, 11, 13, and 17, and in cell cultures of GIST544 (heterozygous KIT exon 9 mutant) þ /À SCF, and GIST882 (homozygous KIT exon 13 mutant) þ /À imatinib, as described for Figure 1 . Upper and lower bands in the phospho-S6K stains are the p85 and p70 isoforms, respectively. The K562 leukemia cells provide a positive control for phospho-STAT5. The GIST cell culture assays demonstrate KIT-dependent activation of MAPK p42/44, AKT, p70S6K, and p85S6K, whereas activation of STAT1 and STAT3 appears to be KIT-independent. STAT5 activation is not seen in any GIST, although total STAT5 expression is generally comparable, or higher, to that in the K562 leukemia control cells. Abbreviations: Ex, exon; Ins, insertion; SCF, stem cell factor; Imat, imatinib because a subset of GISTs manifest resistance to imatinib over time, and complete responses are rare when treating GIST with imatinib as a single agent. Hence, alternative therapeutic strategies are needed. The present study is the first report on KIT signaling in primary GISTs and GIST cell lines identifying activated signaling intermediates that might play essential roles in transmitting the oncogenic KIT signal in GISTs.
We first evaluated KIT tyrosine phosphorylation in primary GISTs using phosphorylation specific antibodies to the GRB2 and PI3-K association sites Y703 and Y721, respectively. The current results confirm and extend previous findings from our group that KIT is tyrosine phosphorylated in most GISTs, irrespective of the genomic mechanism of KIT activation (Rubin et al., 2001) . Expression of phospho-KIT was variable among the primary GISTs, and did not correlate with expression of total KIT, nor apparently with the type of KIT mutation (Figure 1 ). These findings suggest that oncogenic KIT phosphorylation, although generally dependent on an intrinsic genomic mutation, is modulated by other factors in a manner that varies from GIST to GIST. Candidates for such modulatory roles include Janus-activated kinases (JAKs) Weiler et al., 1996) and PI3-K (Duensing and Fletcher, unpublished observations). The fact that expression of total KIT varied substantially in the primary GISTs (Figure 1 ) is in keeping with KIT immunohistochemistry studies, which have also shown variable intralesional KIT expression, along with case-to-case differences in KIT subcellular localization, in primary GISTs .
The data currently available on KIT signaling have been obtained in hematological models or by ectopically expressing GIST type mutations in various cell types. Here, we report, for the first time, studies on KIT signaling in the GIST cell context. We show, in GIST544 cells, that KIT can be activated after exposure to the KIT-ligand SCF. This activation was likely mediated through the wildtype KIT protein since GIST544 cells harbor a heterozygous KIT mutation and thereby coexpress both mutant and the wildtype KIT receptors (Figure 1 ). In contrast, KIT phosphorylation was not increased by SCF treatment in GIST882 cells, which have a homozygous activating KIT mutation (K642E) and do not express wildtype KIT protein (Lux et al., 2000) . These results are consistent with the findings of Chen et al., who did not observe hyperactivation of KIT, MAPK p42/44 and AKT after SCF stimulation of Ba/F3 cells transfected with a K642E KIT mutant (Chen et al., 2003) . Overall, our observation shows that KIT might not be activated maximally in all GISTs, and is in keeping with the notion that a given GIST might have an optimal 'set-point' for KIT activation, depending on the unique biological features of that particular neoplastic clone. GIST544 cells therefore provide the first available model to determine the impact of physiological, nononcogenic KIT activation on GIST signaling mechanisms.
The ubiquitous phosphorylation of the GRB2 and PI3-K association sites KIT Y703 and Y721 in primary GISTs begged the question as to whether signaling through the GRB2/RAS/MAPK and PI3-K/AKT/S6K pathways might be equally ubiquitous in these tumors (Lev et al., 1992; Tsai et al., 1993; Blume-Jensen et al., 1998; Feng et al., 2000; Wu et al., 2000; Chian et al., 2001; Dolci et al., 2001; De Miguel et al., 2002) . In hematological disease there is precedent for selective activation of signaling intermediates by KIT oncoproteins, depending on their intrinsic mutations, and perhaps depending on the cell context in which the oncoproteins are expressed. The highly activated D816V KIT mutant, as found in many cases of mast cell disease, strongly activates the PI3-K/AKT pathway, but not Figure 3 Expression of proliferation markers PCNA, Cyclin A and p27, and PARP cleavage, in immunoblots of total cell lysates from primary GISTs with KIT mutations in exons 9, 11, 13, and 17, and in cell cultures of GIST882 (homozygous KIT exon 13 mutant) þ /À imatinib. Abbreviations: Ex, exon; Ins, insertion; SCF, stem cell factor; Imat, imatinib KIT signaling in gastrointestinal stromal tumors A Duensing et al MAPK p42/44 (Ning et al., 2001b) . Expression of the juxtamembrane region KIT mutant V560G in hematopoietic progenitor cells does not result in activation of MAPK p42/44 or AKT (Frost et al., 2002) . In our study, MAPK p42/44 and members of PI3K pathway were activated in most primary GISTs which is in keeping with studies on wildtype and mutant KIT signaling in various cell contexts other than GIST. Notably, the KIT exon 11 mutant GISTs with stronger AKT phosphorylation generally had higher levels of the proliferation markers cyclin A and PCNA, suggesting that GISTs utilizing the PI3-K/AKT pathway might be associated with a higher proliferation rate and a presumably more aggressive behavior. Furthermore, our in vitro studies demonstrate that activation of MAPK p42/44, AKT, and S6K is partly KIT dependent in GISTs, as evidenced by the activation and inhibition of these kinases after SCF-mediated hyperactivation and imatinib-mediated inhibition in GIST544 and GIST882, respectively.
The facultative role of STAT proteins in KIT signaling has been characterized extensively in non-GIST models (Deberry et al., 1997; Brizzi et al., 1999; Ning et al., 2001a, b) . Activated KIT complexes with STAT1, resulting in STAT1 phosphorylation (Deberry et al., 1997; Brizzi et al., 1999; Ning et al., 2001a, b) . Such interactions between KIT and STAT1 have been observed in all models of KIT activation reported to date, irrespective of whether KIT was activated by ligand or intrinsic mutations (e.g. D816V), and irrespective of whether KIT activation was evaluated in myeloid cells or fibroblasts. By contrast, STAT1 activation in GISTs, although observed frequently (Figure 2) , does not necessarily depend on the oncogenic KIT signal. Neither imatinib-mediated inhibition of mutant KIT, nor ligand-mediated KIT hyperactivation, resulted in substantial modulation of STAT1 phosphorylation (Figure 2b) . Likewise, tyrosine phosphorylation of STAT3 -although variably evident in primary GISTs -was not induced by SCF in GIST544 and was not demonstrably regulated by the KIT oncoprotein in GIST882 (Figure 2b ). This situation contrasts with that for KIT D816V oncoproteins in mast cell disease, which induce constitutive STAT3 activation, and where STAT3 is essential to KIT oncoprotein tumorigenicity and factor-independent growth (Ning et al., 2001b) . Notably, STAT5 phosphorylation was undetectable in all primary GISTs and GIST cell lines, irrespective of the KIT genomic activating mechanisms in those specimens. SCF-mediated activation of wildtype KIT also failed to activate STAT5 (Figure 2b ). This finding is novel because STAT5 activation results from ligandmediated KIT activation in fibroblasts and myeloid cells (Brizzi et al., 1999; Ning et al., 2001b) , suggesting that interacting proteins requisite for STAT5 activation might not be expressed in GIST cells (Lai et al., 1995; Klejman et al., 2002; Nieborowska-Skorska et al., 2002) .
The findings in this series, although preliminary, suggest that the specific KIT mutation type can influence the signal transduction pathways that are activated in a particular GIST. For example, four GISTs with identical exon 9 KIT mutations had low levels of phospho-AKT and phospho-S6K (Figure 2) . However, it is evident that additional mechanisms, besides the intrinsic genomic KIT mutations, influence signaling pathway activation in GISTs. In this regard, the four GISTs with identical exon 9 KIT mutations had variable activation of MAPK p42/44 and STATs (Figure 2a, b) . Moreover, three primary GISTs expressed oncogenic, tyrosine phosphorylated KIT but had no demonstrable activation of any of three signaling intermediates (AKT, MAPK p42/44, and STAT3) that are felt to play key roles in oncogenic kinase signaling generally (Figure 2a,  b) . These observations suggest that other signaling intermediates might play essential roles in oncogenic KIT signaling in some GISTs. Several mechanisms have been reported to modulate KIT signaling in other cell models, but these have not yet been evaluated in GISTs. Such mechanisms include interactions between the SHC adaptor protein and the KIT juxtamembrane region, leading to the activation of the GRB2/RAS/MAPK pathway . It is possible that SHC interactions are perturbed by the KIT juxtamembrane region mutations in some GISTs, therefore contributing to variable activation of MAPK p42/44 (Figure 2 ). Another potential contributor to variable KIT oncoprotein signaling is the expression of different KIT isoforms, resulting from alternative splicing. Such isoforms are associated with variable MAPK activation (Caruana et al., 1999) , perhaps resulting from differential activation of SRC-family kinases and SHC (Voytyuk et al., 2003) . These, and other, interactions might be crucial in determining the selective impact of oncogenic KIT activation in GISTs.
In summary, we have characterized KIT signaling mechanisms in a group of primary GISTs and in two GIST-derived human cell lines. These studies reveal that oncogenic KIT signaling in GISTs differs from that in hematological diseases. STAT5 and JNK activation were not demonstrated in GISTs, and STAT1 and STAT3 activation, although variably detected, were not demonstrably regulated by the oncogenic KIT signal. Variable signaling mechanisms were also manifested by differences in MAPK p42/44 and AKT phosphorylation, even among GISTs with identical KIT mutations. These findings suggest that factors other than KIT regulate signaling pathway activation in GISTs. Finally, our study identified signal transduction pathways that are constitutively activated in a KIT-dependent manner in primary GISTs. Further studies are needed to determine whether these pathways can be targeted to provide synergies with KIT inhibition in GISTs.
Materials and methods
Patients
In total, 15 primary, untreated GISTs were frozen at À801C at time of open biopsy or resection. The histology for all tumors was reviewed by one of the authors (CDMF) and immunohistochemical expression of KIT (present in all cases) was determined using a rabbit polyclonal antibody (A-4052; DAKO, Carpinteria, CA, USA) (Hornick and Fletcher, 2002) . These 15 GISTs were selected from a group of 48 consecutive tumors, for which the KIT mutations have been reported previously (Rubin et al., 2001) . The cases were chosen so as to cover the spectrum of KIT mutations that are known in GISTs, including exon 11 deletion, point missense, and insertion mutations (n ¼ 9). Other cases had exon 9 (AY503-504ins; n ¼ 4), exon 13 (K642E; n ¼ 1), and exon 17 (N822K; n ¼ 1) mutations.
Cell lines
GIST882 is a GIST cell line with an activating homozygous missense mutation in KIT exon 13, encoding a K642E mutant KIT oncoprotein . GIST544 cells were a short-term culture from a GIST with a heterozygous exon 9 KIT mutation (AY503-504ins). Cytogenetic and FISH analyses revealed that more than 95% of the cells in the GIST544 culture were neoplastic cells, with monosomies for chromosomes 14 and 22 (data not shown). K562 is a cell line derived from a BCR-ABL positive chronic myelogenous leukemia (CML) in blast crisis and was obtained from ATCC (Manassas, VI, USA).
Reagents
Stem cell factor (SCF) was obtained from Sigma (St Louis, MO, USA) and reconstituted in PBS/0.1% BSA. Imatinib mesylate was provided by Novartis Pharma (Basel, Switzerland) and reconstituted in DMSO. Polyclonal rabbit antibodies to phospho-KIT Y703 and phospho-KIT Y721 were from Zymed Laboratories (South San Francisco, CA, USA). The specificity of these reagents for tyrosine phosphorylated versus nontyrosine phosphorylated KIT was validated by immunoblotting GIST tissue cultures, before and after inhibition of KIT tyrosine phosphorylation with imatinib, and by immunoblotting the EWS502 Ewing's sarcoma cell line (which expresses total KIT at levels comparable to most GISTs, but with no demonstrable tyrosine phosphorylation) before and after KIT activation by incubation with SCF (data not shown). Additional antibodies from Zymed included a rabbit polyclonal antibody for MAPK p42/44, as well as monoclonal mouse antibodies to phospho-STAT1a/b Y701 (clone ST1P-11A5), total STAT1a (clone ST1-3D4), total STAT3 (clone ST3-5G7), phospho-STAT5 Y694 (clone ST5P-4A9), total pan-STAT5 (clone ST5-8F7), and PARP (clone C-2-10). Polyclonal rabbit antibodies to phospho-AKT S473, total AKT, phospho-S6K T789, phospho-S6K T421/S424, total S6K, phospho-MAPK p42/44 T202/Y204, phospho-STAT3 Y705, and phospho-JNK T183/Y185 were from Cell Signaling (Beverly, MA, USA); mouse monoclonal anti-PCNA (clone PC10) was from Santa Cruz (Santa Cruz, CA, USA); mouse monoclonal anti-p27 (clone 57) was from BD Transduction Laboratories (Lexington, KY, USA), mouse monoclonal anti-Cyclin A (clone 6E6) was from Novocastra (Newcastle upon Tyne, UK); and mouse monoclonal antiactin (clone AC-40) was from Sigma (St Louis, MO, USA).
Functional studies
SCF-mediated KIT activation was evaluated in GIST544 cells, which are heterozygous for a KIT exon 9 mutation, and where native, wildtype KIT proteins are expected to comprise approximately half of the expressed KIT proteins. GIST544 cells were serum-starved for 2 h before incubation with SCF 100 ng/ml for 10 min. Imatinib-mediated inhibition of KIT signaling was evaluated in GIST882 cells, which were exposed to 1 mM imatinib for 4 h in serum-free media. For longer-term studies of KIT inhibition, GIST882 cells were incubated with 1 mM imatinib in serum-containing medium for up to 72 h. Cells were fed with medium containing 1 mM imatinib every day.
Western blotting
Whole cell lysates of frozen tumors were prepared by mincing the specimens on ice in the presence of lysis buffer (1% NP-40, 50 mM Tris-HCl pH 8.0, 100 mM sodium fluoride, 30 mM sodium pyrophosphate, 2 mM sodium molybdate, 5 mM EDTA, 2 mM sodium orthovanadate) containing protease inhibitors (10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride) and additional sodium orthovanadate (2 mM). The tissue was then homogenized using a Tissue Tearort (BioSpec, Bartlesville, OK, USA). For protein lysates from cell lines, monolayers (GIST544, GIST882) were rinsed in Hanks Balanced Salt Solution (HBSS, Gibco Invitrogen, Carlsbad, CA, USA) and scraped into lysis buffer. K562 cells growing in suspension were spun down at 2000 r.p.m. at 41C, washed in HBSS and resuspended in lysis buffer. Lysates were incubated overnight with shaking at 41C, and then clarified by centrifugation for 30 min at 14 000 r.p.m. at 41C. Protein concentrations were determined with the BioRad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). Electrophoresis and immunoblotting were performed as described previously (Rubin et al., 2001) . Blot immunostains were detected by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech), and exposed to X-ray film and developed in a Kodak X-OMAT 2000 film processor (Eastman Kodak, Rochester, NY, USA).
